Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9–16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m 2) were enrolled in a 6‐month, randomized, open‐label, crossover, clinical trial consisting of two, 3‐month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide. Participants were equally randomized to phase‐order (i.e., starting with control or drug therapy) then crossed‐over to the other treatment. BMI, body fat percentage, blood pressure, lipids, oral glucose tolerance tests (OGTT), adipokines, plasma biomarkers of endothelial activation, and endothelial function were assessed at baseline, 3‐, and 6‐months. The mean change over each 3‐month phase was compared between treatments. Compared to control, exenatide significantly reduced BMI (−1.7 kg/m 2, 95% confidence interval (CI) (−3.0, −0.4), P = 0.01), body weight (−3.9 kg, 95% CI (−7.11, −0.69), P = 0.02), and fasting insulin (−7.5 mU/l, 95% CI (−13.71, −1.37), P = 0.02). Significant improvements were observed for OGTT‐derived insulin sensitivity (P = 0.02) and β‐cell function (P = 0.03). Compliance with the injection regimen was excellent (≥94%) and exenatide was generally well‐tolerated (the most common adverse event was mild nausea in 36%). These preliminary data suggest that exenatide should be evaluated in larger, well‐controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Must, A., Jacques, P. F., Dallal, G. E., Bajema, C. J., & Dietz, W. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271904 · Cited by 2,233
Childhood Body-Mass Index and the Risk of Coronary Heart Disease in Adulthood
Baker, J. L., Olsen, L. W., & Sørensen, T. I. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072515 · Cited by 1,679
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“Sibutramine was recently removed from the US market due to cardiovascular safety concerns (16) and orlistat (17) and metformin (18,19) only modestly reduce BMI.”
BackgroundPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 1×
“Area-under-the-curve (AUC) for glucose and insulin, the whole body insulin sensitivity index (WBISI/Matsuda index), and β-cell function were calculated from the OGTT as previously described (22).”
MethodFlegal, K. M., Wei, R., Ogden, C. L., Freedman, D. S., Johnson, C. L., & Curtin, L. R. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28335 · Cited by 435
Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
Yanovski, J. A., Krakoff, J., Salaita, C. G., McDuffie, J. R., Kozlosky, M., Sebring, N. G., Reynolds, J. C., Brady, S. M., & Calis, K. A. (2011) · Diabetes · doi:10.2337/db10-1185 · Cited by 193 · cited 1×
“Sibutramine was recently removed from the US market due to cardiovascular safety concerns (16) and orlistat (17) and metformin (18,19) only modestly reduce BMI.”
Background
Cited by
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
Kumar, S., & Kelly, A. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.017 · Cited by 1,277
Self-citationKelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
“insulin and oral glucose tolerance test–derived markers of insulin resistance and β-cell function.(206) A recent random-”
BackgroundSelf-citationChildhood obesity: increased risk for cardiometabolic disease and cancer in adulthood
Weihrauch-Blüher, S., Schwarz, P., & Klusmann, J.-H. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.001 · Cited by 566
de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 441
Self-citation
Metadata
- Authors
- Kelly, A. S., Metzig, A. M., Rudser, K. D., Fitch, A. K., Fox, C. K., Nathan, B. M., Deering, M. M., Schwartz, B. L., Abuzzahab, M. J., Gandrud, L. M., Moran, A., Billington, C. J., & Schwarzenberg, S. J.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2012-02
- Volume
- 20
- Issue
- 2
- Pages
- 364-370
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2055187870
- Cited by
- 143
- References
- 6
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study. https://app.cochat.ai/papers/10.1038/oby.2011.337
- The paper
- Kelly, A. S., Metzig, A. M., Rudser, K. D., Fitch, A. K., Fox, C. K., Nathan, B. M., Deering, M. M., Schwartz, B. L., Abuzzahab, M. J., Gandrud, L. M., Moran, A., Billington, C. J., & Schwarzenberg, S. J. (2012). Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study. Obesity. https://doi.org/10.1038/oby.2011.337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.